Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Sell
7
HKPD Quote, Financials, Valuation and Earnings
Last price:
$1.17
Seasonality move
:
--
Day range:
$1.07 - $1.35
52-week range:
$1.04 - $3.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
58.2K
Avg. volume:
97.2K
1-year change:
--
Market cap:
$12.2M
Revenue:
$16.7M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | -- | -- | $26.43 |
|
PHBBF
Pharmaron Beijing
|
-- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$12M | -- | 74.63% | -- | $13.00 |
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
$1.11 | -- | $12.2M | -- | $0.00 | 0% | -- |
|
HCM
HUTCHMED (China)
|
$16.06 | $26.43 | $2.7B | 80.30x | $0.00 | 0% | 4.45x |
|
PHBBF
Pharmaron Beijing
|
$1.93 | -- | $2.5B | -- | $0.03 | 1.46% | 1.44x |
|
PRE
Prenetics Global
|
$3.95 | $13.00 | $48.3M | -- | $0.00 | 0% | 1.90x |
|
RGC
Regencell Bioscience Holdings
|
$28.99 | -- | $377.2M | -- | $0.00 | 0% | -- |
|
SBHMY
Sino Biopharmaceutical
|
$9.38 | -- | $8.5B | 17.64x | $0.08 | 2.19% | 2.14x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | 0.000 | -- | -- |
|
HCM
HUTCHMED (China)
|
9.83% | -0.260 | 3.34% | 2.67x |
|
PHBBF
Pharmaron Beijing
|
-- | -0.395 | -- | -- |
|
PRE
Prenetics Global
|
-- | -0.748 | -- | 1.11x |
|
RGC
Regencell Bioscience Holdings
|
-- | -28.439 | -- | -- |
|
SBHMY
Sino Biopharmaceutical
|
23.1% | -0.545 | 14.5% | 1.14x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HKPD
Hong Kong Pharma Digital Technology Holdings
|
-- | -- | -- | -- | -- | -- |
|
HCM
HUTCHMED (China)
|
-- | -- | 4.51% | 4.99% | -- | -- |
|
PHBBF
Pharmaron Beijing
|
-- | -- | -- | -- | -- | -- |
|
PRE
Prenetics Global
|
$3.9M | -$11.8M | -23.16% | -23.16% | -154.7% | -- |
|
RGC
Regencell Bioscience Holdings
|
-- | -- | -- | -- | -- | -- |
|
SBHMY
Sino Biopharmaceutical
|
-- | -- | 6.83% | 8.57% | -- | -- |
Hong Kong Pharma Digital Technology Holdings vs. Competitors
-
Which has Higher Returns HKPD or HCM?
HUTCHMED (China) has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings's net margin of --. Hong Kong Pharma Digital Technology Holdings's return on equity of -- beat HUTCHMED (China)'s return on equity of 4.99%.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings-- -- -- HCMHUTCHMED (China)-- -- $854.7M -
What do Analysts Say About HKPD or HCM?
Hong Kong Pharma Digital Technology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand HUTCHMED (China) has an analysts' consensus of $26.43 which suggests that it could grow by 64.58%. Given that HUTCHMED (China) has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe HUTCHMED (China) is more attractive than Hong Kong Pharma Digital Technology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings0 0 0 HCMHUTCHMED (China)10 2 0 -
Is HKPD or HCM More Risky?
Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HUTCHMED (China) has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.171%.
-
Which is a Better Dividend Stock HKPD or HCM?
Hong Kong Pharma Digital Technology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HUTCHMED (China) offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hong Kong Pharma Digital Technology Holdings pays -- of its earnings as a dividend. HUTCHMED (China) pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or HCM?
Hong Kong Pharma Digital Technology Holdings quarterly revenues are --, which are smaller than HUTCHMED (China) quarterly revenues of --. Hong Kong Pharma Digital Technology Holdings's net income of -- is lower than HUTCHMED (China)'s net income of --. Notably, Hong Kong Pharma Digital Technology Holdings's price-to-earnings ratio is -- while HUTCHMED (China)'s PE ratio is 80.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings is -- versus 4.45x for HUTCHMED (China). Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings-- -- -- -- HCMHUTCHMED (China)4.45x 80.30x -- --
-
Which has Higher Returns HKPD or PHBBF?
Pharmaron Beijing has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings's net margin of --. Hong Kong Pharma Digital Technology Holdings's return on equity of -- beat Pharmaron Beijing's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings-- -- -- PHBBFPharmaron Beijing-- -- -- -
What do Analysts Say About HKPD or PHBBF?
Hong Kong Pharma Digital Technology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Pharmaron Beijing has an analysts' consensus of -- which suggests that it could fall by --. Given that Hong Kong Pharma Digital Technology Holdings has higher upside potential than Pharmaron Beijing, analysts believe Hong Kong Pharma Digital Technology Holdings is more attractive than Pharmaron Beijing.
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings0 0 0 PHBBFPharmaron Beijing0 0 0 -
Is HKPD or PHBBF More Risky?
Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pharmaron Beijing has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HKPD or PHBBF?
Hong Kong Pharma Digital Technology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharmaron Beijing offers a yield of 1.46% to investors and pays a quarterly dividend of $0.03 per share. Hong Kong Pharma Digital Technology Holdings pays -- of its earnings as a dividend. Pharmaron Beijing pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or PHBBF?
Hong Kong Pharma Digital Technology Holdings quarterly revenues are --, which are smaller than Pharmaron Beijing quarterly revenues of --. Hong Kong Pharma Digital Technology Holdings's net income of -- is lower than Pharmaron Beijing's net income of --. Notably, Hong Kong Pharma Digital Technology Holdings's price-to-earnings ratio is -- while Pharmaron Beijing's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings is -- versus 1.44x for Pharmaron Beijing. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings-- -- -- -- PHBBFPharmaron Beijing1.44x -- -- --
-
Which has Higher Returns HKPD or PRE?
Prenetics Global has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings's net margin of -137.21%. Hong Kong Pharma Digital Technology Holdings's return on equity of -- beat Prenetics Global's return on equity of -23.16%.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings-- -- -- PREPrenetics Global50.75% -$0.84 $180.1M -
What do Analysts Say About HKPD or PRE?
Hong Kong Pharma Digital Technology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Prenetics Global has an analysts' consensus of $13.00 which suggests that it could grow by 229.11%. Given that Prenetics Global has higher upside potential than Hong Kong Pharma Digital Technology Holdings, analysts believe Prenetics Global is more attractive than Hong Kong Pharma Digital Technology Holdings.
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings0 0 0 PREPrenetics Global1 0 0 -
Is HKPD or PRE More Risky?
Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prenetics Global has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HKPD or PRE?
Hong Kong Pharma Digital Technology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prenetics Global offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hong Kong Pharma Digital Technology Holdings pays -- of its earnings as a dividend. Prenetics Global pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or PRE?
Hong Kong Pharma Digital Technology Holdings quarterly revenues are --, which are smaller than Prenetics Global quarterly revenues of $7.8M. Hong Kong Pharma Digital Technology Holdings's net income of -- is lower than Prenetics Global's net income of -$10.7M. Notably, Hong Kong Pharma Digital Technology Holdings's price-to-earnings ratio is -- while Prenetics Global's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings is -- versus 1.90x for Prenetics Global. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings-- -- -- -- PREPrenetics Global1.90x -- $7.8M -$10.7M
-
Which has Higher Returns HKPD or RGC?
Regencell Bioscience Holdings has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings's net margin of --. Hong Kong Pharma Digital Technology Holdings's return on equity of -- beat Regencell Bioscience Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings-- -- -- RGCRegencell Bioscience Holdings-- -- -- -
What do Analysts Say About HKPD or RGC?
Hong Kong Pharma Digital Technology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Regencell Bioscience Holdings has an analysts' consensus of -- which suggests that it could fall by --. Given that Hong Kong Pharma Digital Technology Holdings has higher upside potential than Regencell Bioscience Holdings, analysts believe Hong Kong Pharma Digital Technology Holdings is more attractive than Regencell Bioscience Holdings.
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings0 0 0 RGCRegencell Bioscience Holdings0 0 0 -
Is HKPD or RGC More Risky?
Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regencell Bioscience Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HKPD or RGC?
Hong Kong Pharma Digital Technology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regencell Bioscience Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hong Kong Pharma Digital Technology Holdings pays -- of its earnings as a dividend. Regencell Bioscience Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or RGC?
Hong Kong Pharma Digital Technology Holdings quarterly revenues are --, which are smaller than Regencell Bioscience Holdings quarterly revenues of --. Hong Kong Pharma Digital Technology Holdings's net income of -- is lower than Regencell Bioscience Holdings's net income of --. Notably, Hong Kong Pharma Digital Technology Holdings's price-to-earnings ratio is -- while Regencell Bioscience Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings is -- versus -- for Regencell Bioscience Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings-- -- -- -- RGCRegencell Bioscience Holdings-- -- -- --
-
Which has Higher Returns HKPD or SBHMY?
Sino Biopharmaceutical has a net margin of -- compared to Hong Kong Pharma Digital Technology Holdings's net margin of --. Hong Kong Pharma Digital Technology Holdings's return on equity of -- beat Sino Biopharmaceutical's return on equity of 8.57%.
Company Gross Margin Earnings Per Share Invested Capital HKPDHong Kong Pharma Digital Technology Holdings-- -- -- SBHMYSino Biopharmaceutical-- -- $7.2B -
What do Analysts Say About HKPD or SBHMY?
Hong Kong Pharma Digital Technology Holdings has a consensus price target of --, signalling downside risk potential of --. On the other hand Sino Biopharmaceutical has an analysts' consensus of -- which suggests that it could fall by --. Given that Hong Kong Pharma Digital Technology Holdings has higher upside potential than Sino Biopharmaceutical, analysts believe Hong Kong Pharma Digital Technology Holdings is more attractive than Sino Biopharmaceutical.
Company Buy Ratings Hold Ratings Sell Ratings HKPDHong Kong Pharma Digital Technology Holdings0 0 0 SBHMYSino Biopharmaceutical0 0 0 -
Is HKPD or SBHMY More Risky?
Hong Kong Pharma Digital Technology Holdings has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sino Biopharmaceutical has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.775%.
-
Which is a Better Dividend Stock HKPD or SBHMY?
Hong Kong Pharma Digital Technology Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sino Biopharmaceutical offers a yield of 2.19% to investors and pays a quarterly dividend of $0.08 per share. Hong Kong Pharma Digital Technology Holdings pays -- of its earnings as a dividend. Sino Biopharmaceutical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HKPD or SBHMY?
Hong Kong Pharma Digital Technology Holdings quarterly revenues are --, which are smaller than Sino Biopharmaceutical quarterly revenues of --. Hong Kong Pharma Digital Technology Holdings's net income of -- is lower than Sino Biopharmaceutical's net income of --. Notably, Hong Kong Pharma Digital Technology Holdings's price-to-earnings ratio is -- while Sino Biopharmaceutical's PE ratio is 17.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hong Kong Pharma Digital Technology Holdings is -- versus 2.14x for Sino Biopharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HKPDHong Kong Pharma Digital Technology Holdings-- -- -- -- SBHMYSino Biopharmaceutical2.14x 17.64x -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is down 0.57% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 7.98% over the past day.
